← Agilent overview

Agilent vs Thermo Fisher Scientific: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Agilent Technologies Inc (A)

Q3 2026
▲3

Agilent Q3 Beat, China Rebound, Reshoring Orders Drive August Gains

  • Q3 earnings beat and raised guidance Agilent beat Q3 estimates with 18% EPS growth and raised full-year guidance, sending shares up 9.6%. This shows the company is growing faster than expected and gives investors confidence in its momentum.

    This is the main new financial event that directly boosted the stock in August.

  • China rebound and reshoring orders China rebounded with double-digit pharma growth, and Agilent booked its first reshoring orders from five top-10 pharma companies. This reduces reliance on any single market and taps new demand as drug production moves closer to home.

    These are new geographic and customer wins that expand Agilent's revenue base.

  • Diagnostics expansion via FDA/EU approvals Agilent won FDA and EU approvals for PD-L1 cancer tests, expanding its diagnostics business. This opens new revenue streams in cancer care and strengthens its position in the fast-growing pathology market.

    New product approvals are concrete growth catalysts for the diagnostics segment.

  • AI and automation tailwinds vs. competition and sector sensitivity AI product launches, lab automation, and multi-year instrument replacement cycles add steady tailwinds. But Danaher's Leica is expanding in pathology, and the life sciences tools sector remains sensitive to growth-outlook cuts, which could cap gains if investors worry about market share or a broader slowdown.

    This captures both the positive long-term drivers and the real risks that could limit upside.

August 2026
▲3

Agilent Q3 Beat, China Rebound, Reshoring Orders Drive August Gains

  • Q3 earnings beat and raised guidance Agilent beat Q3 estimates with 18% EPS growth and raised full-year guidance, sending shares up 9.6%. This shows the company is growing faster than expected and gives investors confidence in its momentum.

    This is the main new financial event that directly boosted the stock in August.

  • China rebound and reshoring orders China rebounded with double-digit pharma growth, and Agilent booked its first reshoring orders from five top-10 pharma companies. This reduces reliance on any single market and taps new demand as drug production moves closer to home.

    These are new geographic and customer wins that expand Agilent's revenue base.

  • Diagnostics expansion via FDA/EU approvals Agilent won FDA and EU approvals for PD-L1 cancer tests, expanding its diagnostics business. This opens new revenue streams in cancer care and strengthens its position in the fast-growing pathology market.

    New product approvals are concrete growth catalysts for the diagnostics segment.

  • AI and automation tailwinds vs. competition and sector sensitivity AI product launches, lab automation, and multi-year instrument replacement cycles add steady tailwinds. But Danaher's Leica is expanding in pathology, and the life sciences tools sector remains sensitive to growth-outlook cuts, which could cap gains if investors worry about market share or a broader slowdown.

    This captures both the positive long-term drivers and the real risks that could limit upside.

Latest
▲4

Agilent's Q3 beat and China/reshoring momentum drive shares higher

  • Q3 earnings beat and raised guidance Agilent beat Q3 estimates with non-GAAP EPS up 18% and raised full-year guidance, sending shares up 9.6% since the report. Broad demand across pharma and China, plus Advanced Therapeutics up nearly 30%, shows the core business is accelerating and supports a higher stock price.

    This is the biggest new positive catalyst this period, directly driving the stock higher.

  • China strength and reshoring orders Management said China delivered double-digit growth in pharma and food and high-teens in advanced materials, and Agilent booked its first reshoring orders from five top-10 pharma companies. This opens a new demand source and supports long-term growth, pushing the stock up.

    New geographic and reshoring demand drivers that were not previously reported and directly boost growth outlook.

  • Instrument replacement cycle and lab automation Agilent is less than halfway through its liquid chromatography replacement cycle, worth 200-300 basis points of growth, and about a quarter through gas chromatography, worth 100 basis points. These multi-year upgrades plus lab automation provide a steady tailwind for revenue and the stock.

    New details on replacement cycles and automation that underpin future growth, not previously reported.

  • New AI product launches and investment Agilent launched a Gen5 AI cell identification module for BioTek imagers and led a multimillion-dollar investment in HALO X-ray Technologies. These moves expand its AI and security screening offerings, signaling innovation that can drive future sales and support the stock.

    New product and investment news that shows Agilent is advancing technology, a positive for future growth.

▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

  • AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.

    New product and guidance signal future growth, a key driver for the stock.

  • FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.

    Regulatory wins open new markets and deepen partnerships, directly boosting future sales.

  • Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.

    Guidance raise and China recovery are the biggest new fundamental drivers for the stock.

  • Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.

    Provides a fair counterweight to the positive news, showing what could hold the stock back.

Q2 2026
▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

June 2026
▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

Thermo Fisher Scientific Inc (TMO)

Q3 2026
▲2▼1

Thermo Fisher Q3: Strong Q2 Results and New Wins, but China and Tariffs Weigh

  • Q2 Earnings Beat and Raised Guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating estimates. Management raised full-year guidance, and the stock jumped 8.7% to $572.32 as analysts lifted targets.

    This is the main positive force that drove the stock price during the quarter.

  • New Partnerships and Product Approvals Thermo Fisher announced an ImmuPharma manufacturing partnership, received FDA clearance for the EXENT myeloma test, and formed a Mayo Clinic venture called Precure. These expand its service offerings and add potential revenue streams.

    These new business wins support future growth and investor confidence.

  • Microbiology Sale Completed Thermo Fisher completed the $1.075 billion sale of its microbiology business. The deal frees up cash for other investments but trims near-term revenue, creating a mixed impact on the stock.

    This strategic move has both positive and negative implications for the company's financials.

  • China Weakness and Tariff Uncertainty China's academic and government demand remained weak, Asia-Pacific slightly missed expectations, and tariff uncertainty lingered. HSBC cut its target to $540, a real counterweight to the recovery.

    These risks put downward pressure on the stock and limit upside potential.

August 2026
▲3▼1

Thermo Fisher's recovery broadens, but China and tariffs weigh

  • FDA clears EXENT myeloma test The FDA cleared Thermo Fisher's EXENT myeloma test, a new product for diagnosing a type of blood cancer. This opens a fresh revenue stream and shows the company's testing business can grow beyond its current lineup.

    New product approval is a fresh positive driver for future sales.

  • Mayo Clinic Precure venture and new partnerships Thermo Fisher formed a venture with Mayo Clinic called Precure and announced other new products and partnerships. These deals broaden its future revenue sources and show its services remain in demand, supporting the stock.

    New collaborations expand future revenue and are new to this period.

  • Completed $1.075B microbiology sale Thermo Fisher completed the sale of its microbiology business for $1.075 billion. This frees up cash that can be used for other investments or debt reduction, but it also removes some near-term revenue, so the effect is mixed.

    Completing a major divestiture is a new event with mixed implications.

  • China weakness and tariff risks persist China's academic and government demand remains weak, Asia-Pacific missed slightly, and tariff risks continue. HSBC cut its target to $540, highlighting these as real counterweights to the recovery.

    These are ongoing risks that cap upside and are new details this period.

Latest
▲4

Thermo Fisher's recovery broadens as new products and deals build

  • Analysts raise targets after Q2 beat After Thermo Fisher's strong Q2, Simply Wall St lifted its fair value to $631 from $591, and Morgan Stanley, Barclays, BofA and Jefferies raised targets into the $630-650 range. Higher targets pull the stock up because they signal analysts expect more profit ahead. HSBC cut to $540, a real counterweight.

    Shows the market's upgraded view of TMO's value after results, a direct price driver.

  • Microbiology sale completed for $1.075 billion Thermo Fisher finished selling its microbiology business to Astorg for about $1.075 billion in cash plus a $50 million seller note. The unit had $645 million of 2025 revenue. Cash from the sale can fund buybacks or growth areas, but it also removes revenue near term, so the effect is mixed.

    A completed major transaction that changes TMO's business mix and cash position.

  • New products and partnerships widen offerings Thermo Fisher launched the EMPAD G2 electron detector, the Gibco CHO-K1 cell-culture panel, and agreed to resell Evosep's Eno proteomics platform. It also joined a Digital CMC Consortium and expanded cancer-monitoring work. These add future sales in instruments, bioprocessing and proteomics, supporting the stock.

    Product launches and deals are the main new growth drivers this period.

  • International revenue beats, China still a risk June-quarter revenue of $11.99 billion beat expectations, with Europe and other regions ahead of forecasts, though Asia-Pacific fell slightly short. Management said China returned to growth but academic and government demand there stayed weak, and tariff risks remain. Broad recovery supports the stock, but China is a real drag.

    Shows the geographic demand picture behind TMO's revenue beat and the key risk.

▲4

Thermo Fisher's Life-Sciences Recovery Gains Steam as New Deals and Clearances Build

  • Q2 beat and raised guidance Thermo Fisher reported 10% revenue growth to $11.99 billion and 13% EPS growth, then raised full-year revenue guidance to $47.4–$48.1 billion. Analysts lifted price targets, with RBC going to $580 from $490. Strong results and a brighter outlook push the stock up because investors pay more for faster, more reliable profit growth.

    This is the core new event that reset expectations for the company's earnings power.

  • Broad demand recovery, outpacing Danaher Organic revenue rose 5% and management pointed to improving customer activity across pharma and biotech, while the Analytical Instruments unit returned to growth after two weak years. Rival Danaher cut its growth outlook, so Thermo Fisher looks like a share gainer. A recovering end-market lifts the stock because it suggests the slump in life-sciences spending is ending.

    It shows the demand recovery is real and Thermo Fisher is winning relative to a key competitor.

  • FDA clearance for EXENT myeloma test Thermo Fisher won FDA 510(k) clearance for its EXENT automated mass-spectrometry platform for multiple myeloma, strengthening its specialty cancer diagnostics. New approved products open fresh revenue streams and support higher-margin recurring sales, which investors view as a durable positive for the stock.

    A new regulatory approval expands the product portfolio and future revenue.

  • Mayo Clinic Precure venture Thermo Fisher became a minority owner in Precure, LLC, a Mayo Clinic-led venture building molecular data from one million biospecimens, contributing its Olink proteomics platform, Orbitrap mass spectrometers, kits and reagents. The deal creates a large new outlet for its products and validates its technology, supporting the stock.

    A new partnership provides a visible long-term demand channel for Thermo Fisher's instruments and reagents.

July 2026
▲3

Thermo Fisher Q2 Beat and Raised Guidance Drive Stock Higher

  • Q2 earnings beat and raised full-year guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating expectations. Management raised full-year revenue and EPS guidance, signaling confidence in continued momentum. This directly boosts the stock as it shows the company is growing faster than expected and expects that to continue.

    This is the core new event that answers why the stock is moving now.

  • Stock jumps 8.7% on earnings and analyst upgrades Shares climbed 8.7% to $572.32 after the earnings report, and three analysts raised their price targets, with Jefferies going to $630. Upgrades from Wall Street often pull in more buyers, pushing the price higher in the short term and reflecting improved sentiment.

    This shows the immediate market reaction and analyst validation, which are key to the price move.

  • New manufacturing partnership with ImmuPharma Thermo Fisher was selected by ImmuPharma to make its diabetes treatment Kapiglucagon. This adds a new project to Thermo Fisher's drug manufacturing services, bringing in potential future revenue and showing that its services are in demand. It supports the stock by expanding its business.

    This is a new contract that adds to the growth story and supports the positive outlook.

▲3

Thermo Fisher Q2 Beat and Raised Guidance Drive Stock Higher

  • Q2 earnings beat and raised full-year guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating expectations. Management raised full-year revenue and EPS guidance, signaling confidence in continued momentum. This directly boosts the stock as it shows the company is growing faster than expected and expects that to continue.

    This is the core new event that answers why the stock is moving now.

  • Stock jumps 8.7% on earnings and analyst upgrades Shares climbed 8.7% to $572.32 after the earnings report, and three analysts raised their price targets, with Jefferies going to $630. Upgrades from Wall Street often pull in more buyers, pushing the price higher in the short term and reflecting improved sentiment.

    This shows the immediate market reaction and analyst validation, which are key to the price move.

  • New manufacturing partnership with ImmuPharma Thermo Fisher was selected by ImmuPharma to make its diabetes treatment Kapiglucagon. This adds a new project to Thermo Fisher's drug manufacturing services, bringing in potential future revenue and showing that its services are in demand. It supports the stock by expanding its business.

    This is a new contract that adds to the growth story and supports the positive outlook.

Q2 2026
▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

  • AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.

    This is a major new strategic push that could drive future revenue and investor optimism.

  • Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.

    It highlights a favorable industry trend that directly benefits TMO's core business.

  • Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.

    It explains a recent negative price reaction that may still affect investor sentiment.

  • New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.

    These are concrete new business wins that can drive revenue and show competitive strength.

June 2026
▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

  • AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.

    This is a major new strategic push that could drive future revenue and investor optimism.

  • Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.

    It highlights a favorable industry trend that directly benefits TMO's core business.

  • Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.

    It explains a recent negative price reaction that may still affect investor sentiment.

  • New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.

    These are concrete new business wins that can drive revenue and show competitive strength.

▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

  • AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.

    This is a major new strategic push that could drive future revenue and investor optimism.

  • Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.

    It highlights a favorable industry trend that directly benefits TMO's core business.

  • Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.

    It explains a recent negative price reaction that may still affect investor sentiment.

  • New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.

    These are concrete new business wins that can drive revenue and show competitive strength.